NEW YORK, Oct. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Generics/Biosimilars Collection - Report Bundle consists of all 4 reports from our Generics/Biosimilars Report Series.
Reports Included 1. Charting the Biosimilar and Biobetter Development Pipeline (2013) (July 2013)
2. Biosimilar Defensive Plays -- assessing the options (June 2013)
3. Branded Generics: Strategies and Tactics for Winning in Latin America (April 2013)
4. Biosimilars in Emerging Markets (Volume 1 and Volume 2) (March 2013)
Charting the Biosimilar and Biobetter Development Pipeline (2013)
If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical.
The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin, Remicade and Humira, losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the demand of health payers for low cost medicines, the drive to develop a viable biosimilar market will continue to grow.
Who are the companies involved? What does their portfolio look like? What stage are they at? Which products offer the best potential in terms of competitor development? Critical questions needing robust answers. Th
Copyright©2012 PR Newswire.
All rights reserved